Press Releases Ribomic Inc.

Equities

4591

JP3974850004

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-15 EDT			5-day change	1st Jan Change
85 ^JPY	0.00%		+1.19%	-21.30%

03-07	Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI
02-20	Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	12-05	BU
RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	22-07-29	PU
Ribomic : 【Delayed】RIBOMIC Announces Publication Highlighting Novel Approach to Generate Aptamer using AI in the Nature Computational Science	22-06-10	PU
RIBOMIC : Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia	22-04-19	PU
RIBOMIC : Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration	22-03-23	PU
RIBOMIC : Announces Presentation Materials of the 40th Annual J.P. Morgan Healthcare Conference	22-01-11	PU
RIBOMIC : Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration	21-12-28	PU
RIBOMIC : Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference	21-12-23	PU
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia	21-11-15	BU
RIBOMIC : Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia	21-11-15	PU
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2021(Based on Japanese GAAP)	21-11-09	PU
RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting	21-09-30	BU
RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet AMD at the Retina Society 2021 Meeting	21-09-30	PU
RIBOMIC : Completes Patient Enrollment of its US Phase 2 Open-Label Extension Clinical Trial of RBM-007 for wet AMD (RAMEN Study)	21-08-30	PU
RIBOMIC : Completes Patient Enrollment of its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (TOFU Study)	21-08-04	PU
RIBOMIC : Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in treatment naive wet AMD Patients	21-07-12	PU
RIBOMIC : Announces Termination of MTA with The Pritzker Neuropsychiatric Disorders Research Consortium	21-05-28	PU
Ribomic : Summary of Non-Consolidated Financial Results for the Year Ended March 31, 2021 (Based on Japanese GAAP)	21-05-25	PU
RIBOMIC : Announces Completion of its Phase I Trial of RBM-007 for the Treatment of Achondroplasia	21-05-21	PU
RIBOMIC : Announces Publication of a Research Paper on an Aptamer Creation Platform Technology for Membrane Receptor GPCR	21-05-21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ribomic Inc.

Equities

4591

JP3974850004

Press Releases

Filters